文献速递免疫规划传染病防控与疫情报告

自扩增RNA疫苗在传播-攻击仓鼠模型中预防SARS-CoV-2(D614G)和Alpha变异株(B.1.1.7)

A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model.
PubMed 文献 · Vaccine · 2022-04-01

研究在叙利亚金黄仓鼠中建立传播-攻击模型,评估基于早期武汉样病毒刺突序列的自扩增RNA(saRNA)疫苗。免疫仓鼠血清中和抗体滴度与人类恢复期血清或疫苗接种者相似,疫苗能消除接触感染2020年夏季分离病毒或2020年12月分离的Alpha(B.1.1.7)变异株的仓鼠的临床体征,并减少鼻腔感染性病毒排出。

要点

  • saRNA疫苗诱导的中和抗体滴度与人类恢复期血清或疫苗接种者相似
  • 疫苗同等有效地消除接触感染2020年夏季病毒或Alpha变异株仓鼠的临床体征
  • 疫苗减少鼻腔感染性病毒排出,可能降低 onward 传播

核心结论

  • 基于早期武汉样病毒刺突序列的saRNA疫苗在传播-攻击仓鼠模型中能消除临床体征并减少鼻腔病毒排出,该模型可扩展用于测试新变异株。

研究设计与样本

  • 研究使用叙利亚金黄仓鼠建立传播-攻击模型,以更自然的剂量和途径感染,替代常规鼻内攻击。

主要发现

  • 免疫仓鼠血清中和抗体滴度与人类恢复期血清或疫苗接种者相似。
  • 疫苗同等有效地消除接触感染2020年夏季分离病毒或2020年12月分离的Alpha(B.1.1.7)变异株仓鼠的临床体征。
  • 疫苗减少鼻腔感染性病毒排出。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccines for SARS-CoV-2 have been hugely successful in alleviating hospitalization and deaths caused by the newly emerged coronavirus that is the cause of COVID. However, although the parentally administered vaccines are very effective at reducing severe disease, they do not induce sterilizing immunity. As the virus continues to circulate around the globe, it is still not clear how long protection will last, nor whether variants will emerge that escape vaccine immunity. Animal models can be useful to complement studies of antigenicity of novel variants and inform decision making about the need for vaccine updates. The Syrian golden hamster is the preferred small animal model for SARS-CoV-2 infection. Since virus is efficiently transmitted between hamsters, we developed a transmission challenge model that presents a more natural dose and route of infection than the intranasal challenge usually employed. Our studies demonstrate that an saRNA vaccine based on the earliest Wuhan-like virus spike sequence induced neutralizing antibodies in sera of immunized hamsters at similar titres to those in human convalescent sera or vaccine recipients. The saRNA vaccine was equally effective at abrogating clinical signs in animals who acquired through exposure to cagemates infected either with a virus isolated in summer 2020 or with a representative Alpha (B.1.1.7) variant isolated in December 2020. The vaccine also reduced shedding of infectious virus from the nose, further reinforcing its likely effectiveness at reducing onwards transmission. This model can be extended to test the effectiveness of vaccination in blocking infections with and transmission of novel variants as they emerge.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Frise R, Baillon L, Zhou J, et al. A self-amplifying RNA vaccine protects against SARS-CoV-2 (D614G) and Alpha variant of concern (B.1.1.7) in a transmission-challenge hamster model. Vaccine. 2022. PMID: 35396165. doi:10.1016/j.vaccine.2022.03.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。